Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v11-FR Version v1-EN
Language French English
Date Updated 2024-02-02 2020-12-03
Drug Identification Number 02483939 02483939
Brand name NAT-ERLOTINIB NAT-ERLOTINIB
Common or Proper name Erlotinib Hydrochloride Erlotinib Hydrochloride
Company Name NATCO PHARMA (CANADA) INC NATCO PHARMA (CANADA) INC
Ingredients ERLOTINIB ERLOTINIB
Strength(s) 150MG 150MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size Bottle of 30's Bottle of 30's
ATC code L01XE L01XE
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2020-12-01 2020-12-01
Actual start date 2020-12-01 2020-12-01
Estimated end date 2025-06-30 2021-12-31
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Long Term Back order Long Term Back order
Health Canada comments